Literature DB >> 10626817

MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte.

M I Nishimura1, D Avichezer, M C Custer, C S Lee, C Chen, M R Parkhurst, R A Diamond, P F Robbins, D J Schwartzentruber, S A Rosenberg.   

Abstract

It is generally considered that MHC class I-restricted antigens are recognized by CD8+ T cells, whereas MHC class II-restricted antigens are recognized by CD4+ T cells. In the present study, we report an MHC class I-restricted CD4+ T cell isolated from the tumor infiltrating lymphocytes (TILs) of a patient with metastatic melanoma. TIL 1383 I recognized HLA-A2+ melanoma cell lines but not autologous transformed B cells or fibroblasts. The antigen recognized by TIL 1383 I was tyrosinase, and the epitope was the 368-376 peptide. Antibody blocking assays confirmed that TIL 1383 I was MHC class I restricted, and the CD4 and CD8 coreceptors did not contribute significantly to antigen recognition. TIL 1383 I was weakly cytolytic and secreted cytokines in a pattern consistent with it being a Th1 cell. The avidity of TIL 1383 I for peptide pulsed targets is 10-100-fold lower than most melanoma-reactive CD8+ T cell clones. These CD4+ T cells may represent a relatively rare population of T cells that express a T-cell receptor capable of cross-reacting with an MHC class I/peptide complex with sufficient affinity to allow triggering in the absence of the CD4 coreceptor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10626817

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients.

Authors:  Sergiusz Markowicz; Zbigniew I Nowecki; Piotr Rutkowski; Andrzej W Lipkowski; Marzena Biernacka; Anna Jakubowska-Mucka; Tomasz Switaj; Aleksandra Misicka; Henryk Skurzak; Hanna Polowniak-Pracka; Jan Walewski
Journal:  Med Oncol       Date:  2012-12       Impact factor: 3.064

2.  Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses.

Authors:  Richard C Koya; Stephen Mok; Begoña Comin-Anduix; Thinle Chodon; Caius G Radu; Michael I Nishimura; Owen N Witte; Antoni Ribas
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

3.  Gut microbiota amplifies host-intrinsic conversion from the CD8 T cell lineage to CD4 T cells for induction of mucosal immune tolerance.

Authors:  Jen Bon Lui; Lander S McGinn; Zhibin Chen
Journal:  Gut Microbes       Date:  2016

4.  Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death.

Authors:  Matthew J Scheffel; Gina Scurti; Patricia Simms; Elizabeth Garrett-Mayer; Shikhar Mehrotra; Michael I Nishimura; Christina Voelkel-Johnson
Journal:  Cancer Res       Date:  2016-10-15       Impact factor: 12.701

5.  Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.

Authors:  Cyrille J Cohen; Jared J Gartner; Miryam Horovitz-Fried; Katerina Shamalov; Kasia Trebska-McGowan; Valery V Bliskovsky; Maria R Parkhurst; Chen Ankri; Todd D Prickett; Jessica S Crystal; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins
Journal:  J Clin Invest       Date:  2015-09-21       Impact factor: 14.808

6.  Knockdown of T-bet expression in Mart-127-35 -specific T-cell-receptor-engineered human CD4(+)  CD25(-) and CD8(+) T cells attenuates effector function.

Authors:  Sidharth S Jha; Nitya G Chakraborty; Prashant Singh; Bijay Mukherji; David I Dorsky
Journal:  Immunology       Date:  2015-05       Impact factor: 7.397

7.  Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation.

Authors:  Jonathan M Eby; Hee-Kap Kang; Jared Klarquist; Shilpak Chatterjee; Jeffrey A Mosenson; Michael I Nishimura; Elizabeth Garrett-Mayer; B Jack Longley; Victor H Engelhard; Shikhar Mehrotra; I Caroline Le Poole
Journal:  Pigment Cell Melanoma Res       Date:  2014-07-21       Impact factor: 4.693

8.  Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines.

Authors:  Steven A Rosenberg; Richard M Sherry; Kathleen E Morton; James C Yang; Suzanne L Topalian; Richard E Royal; Udai S Kammula; Nicholas P Restifo; Marybeth S Hughes; Susan L Schwarz; Lien T Ngo; Sharon A Mavroukakis; Donald E White
Journal:  J Immunother       Date:  2006 Mar-Apr       Impact factor: 4.456

9.  Human antigen-specific regulatory T cells generated by T cell receptor gene transfer.

Authors:  Todd M Brusko; Richard C Koya; Shirley Zhu; Michael R Lee; Amy L Putnam; Stephanie A McClymont; Michael I Nishimura; Shuhong Han; Lung-Ji Chang; Mark A Atkinson; Antoni Ribas; Jeffrey A Bluestone
Journal:  PLoS One       Date:  2010-07-22       Impact factor: 3.240

10.  Lack of p53 Augments Antitumor Functions in Cytolytic T Cells.

Authors:  Anirban Banerjee; Krishnamurthy Thyagarajan; Shilpak Chatterjee; Paramita Chakraborty; Pravin Kesarwani; Myroslawa Soloshchenko; Mazen Al-Hommrani; Kristina Andrijauskaite; Kelly Moxley; Harinarayanan Janakiraman; Matthew J Scheffel; Kristi Helke; Kent Armenson; Viswanathan Palanisamy; Mark P Rubinstein; Elizabeth-Garrett Mayer; David J Cole; Chrystal M Paulos; Michael I Nishimura; Shikhar Mehrotra
Journal:  Cancer Res       Date:  2016-07-27       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.